Navigation Links
Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers

FORT WORTH, Texas, July 30 /PRNewswire/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM), announced today an evidence based study with a NE podiatric clinic evaluating the clinical performance of their advanced wound care collagen product, CellerateRx(R), on diabetic venous ulcers. "According to data released by the Centers for Disease Control and Prevention, diabetes now affects nearly 24 million people in the United States alone," states Cathy Bradshaw, President of Wound Care Innovations. Venous stasis ulcers of the lower extremity is a common problem among diabetic patients and presents significant quality of life issues for them as well as tremendous costs to the healthcare system. It has been estimated that venous ulcers cause the loss of approximately 2 million working days and incur treatment costs of approximately $3 billion per year in the United States.(1) "We have had very positive feedback from clinicians using CellerateRx(R) on these types of wounds. We look forward to providing this data to the medical community," Bradshaw said.

(1) New England Journal of Medicine, Bergan et al

About Wound Management Technologies, Inc.:

Wound Management Technologies, Inc. (WNDM), Worth, Texas, markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information visit .

"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

SOURCE Wound Management Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Derma Sciences to Enter Phase II Development of Wound Healing Product That May Use Bodys Own Naturally Occurring Stem Cells
2. Aung FootHealth Clinics & Advanced Wound Care Center Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Trial
3. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
4. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
5. Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial
6. Wound Management Technologies, Inc. Announces Evidence Based Study
7. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
8. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
9. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
10. Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
11. U.S. Preventive Medicine Acquires Specialty Disease Management
Post Your Comments:
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas ... Brasil as the company,s second affiliate in Latin America . ... ... of Astellas Farma Colombia ... ...
(Date:6/23/2016)... The vast majority of dialysis patients currently ... are usually 3 times a week, with treatment times ... time, equipment preparation and wait time.  This regimen can ... patients who are elderly and frail.  Many elderly dialysis ... centers for some duration of time. Residents ...
(Date:6/23/2016)... June 23, 2016 The Biotechnology ... continues to present great opportunities to investors. assesses ... Intrexon Corp. (NYSE: XON ), Vertex Pharmaceuticals ... (NASDAQ: ARNA ), and Regeneron Pharmaceuticals Inc. ... stocks and receive your complimentary trade alerts at: ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic ... World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. ... some of the world’s leading providers of cereal and other breakfast foods. Its residents ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
Breaking Medicine News(10 mins):